Lung Cancer News and Research

RSS

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Treatment with common allergy medication linked to improved immunotherapy response

New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.

29 Nov 2021

Cancer cells disarm immune cells by hijacking mitochondria, says research

Researchers utilized the power of nanotechnology to identify a novel means that cancer cells use to disarm their would-be cellular attackers.

19 Nov 2021

New model for early prediction of cancer patients' response to immunotherapy

Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.

10 Nov 2021

Study reveals what causes T cells to be non-responsive to immunotherapy

Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are "exhausted" and have stopped working.

1 Nov 2021

Molecular atlas of small cell lung cancer reveals signatures of metastasis and immunosuppression

Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.

15 Oct 2021

New study reveals lung cell roles in guiding the immune system

Lung immunity is essential to combat all pulmonary diseases, including COVID-19, pneumonia, lung cancer, asthma and COPD.

6 Oct 2021

Researchers find a new way to counter immunosuppressive effect in tumors

Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.

21 Sep 2021

Vaccinating against certain cancer proteins can boost overall immune response and shrink tumors

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.

17 Sep 2021

Novel nanofluidic device for exosome nanoporation

A team of researchers described an innovative nanofluidic device for high-throughput preparation of exosome-based drug delivery vehicles.

8 Sep 2021

Stem-like T cells found in certain lymph nodes could be natural cancer fighters

Researchers performed a new study and demonstrated that stem-like T cells found in some lymph nodes could exhibit natural cancer-fighting properties.

7 Sep 2021

Scientists develop lung organoids to imitate actual SARS-CoV-2 infection

The emergence of the COVID-19 pandemic in the United States in early 2020 left researchers struggling to identify lab models of SARS-CoV-2 infection.

From UC San Diego 2 Sep 2021

New molecule can effectively deplete cancer-protecting cells inside tumors

A new study has discovered a two-arm molecule that can effectively deplete cancer-protecting cells within tumors.

16 Aug 2021

New technique to hunt down mutations that cause cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

11 Aug 2021

Research provides a detailed 'proteogenomic' view of lung squamous cell carcinoma

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.

6 Aug 2021

New multimodal diagnostic can detect cancer cells and pinpoint tumor location

Most of the tests that doctors use to diagnose cancer -- such as mammography, colonoscopy, and CT scans -- are based on imaging. More recently, researchers have also developed molecular diagnostics that can detect specific cancer-associated molecules that circulate in bodily fluids like blood or urine.

19 Jul 2021

Natural killer cells target breast cancer using the body’s immune system

In a recent study, researchers investigated how natural killer cells target breast cancer using the body's own immune system.

18 Jun 2021

Breast cancer survivors have higher risk of new cancer diagnosis compared to healthy individuals

A new study finds breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, which appears in CANCER, states that compared to the general population in the United States, the risk of new cancer diagnoses among survivors was 20% higher for those with hormone receptor (HR) positive cancers and 44% higher for those with HR-negative cancers.

19 May 2021

Modified immune cells can ruthlessly kill cancerous tumors

Modified immune cells that ruthlessly kill cancerous tumors may prove a game-changer for people living with late-stage cancer.

16 Apr 2021

Researchers identify and test drug combination that exploits a weakness in small cell lung cancer

Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer.

13 Apr 2021

Scientists discover mutations that make cancer resistant to KRAS-targeted therapies

A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.

7 Apr 2021